The Xconomy Awards categories weren’t enough to capture the full diversity of the San Diego life science community. So we at Xconomy created X of the Year for people who are so unique they needed their own categories. Read on for short introductions of the X of the Year finalists. This is part of a […]

It finally is starting to feel like spring in Boston, which means our annual half-day life science forum, “What’s Hot in Boston Biotech,” is just around the corner. It’s happening on Tuesday, May 21, at Bristol-Myers Squibb in Cambridge, MA. We’re convening an elite and eclectic group of life sciences executives, researchers, and investors from […]

It will be hard to top last year’s flurry of biotech companies joining the public markets, but this week is shaping up to be the busiest for life science IPOs in recent memory. Five biotechs priced their IPOs and at least one more is coming. According to IPO research firm Renaissance Capital, 47 IPOs have […]

Grab your ticket now to attend Life Science Xchange: Closer to Convergence. Join Xconomy on June 25 at Cambia Grove in Seattle to hear the stories of local organizations taking advantage of the growing convergence of biology and data to discover, develop, and deliver healthcare innovation to patients— in the form of drugs, diagnostics, devices, […]

The American Academy of Neurology meeting in Philadelphia is rolling on through the end of this week. There has been plenty of news to digest already. New clinical data could herald cutting-edge treatments for migraine, the rare disease spinal muscular atrophy, the deadly neurological disorder amyotrophic lateral sclerosis, and more. Xconomy previewed the conference last […]

A new startup wants to edit out the world’s biggest killer. Prominent cardiologist and geneticist Sekar Kathiresan is heading up a new company, Verve Therapeutics, that will develop gene-altering medicine to prevent heart attacks. Heart disease is the leading cause of death in the US and worldwide. “Imagine an injection, once in life, that safely […]

William Grossman has joined Arcus Biosciences (NYSE: RCUS) as chief medical officer, the same position he held at his former company, Bellicum Pharmaceuticals (NASDAQ: BLCM). Grossman’s experience also includes positions at Genentech, AbbVie (NYSE: ABBV), and Biothera. Hayward, CA-based Arcus, which raised $120 million in its IPO last year, has several cancer drugs in early-stage […]

The first new class of migraine drugs in decades won FDA approval last year. But the companies who commercialized these new therapies and their potential competitors are already planning new, more convenient versions, taken as pills instead of injectoins just below the skin, and they will present key data in the next few days at […]

Maria Koehler has been appointed executive vice president and chief medical officer of Repare Therapeutics. Koehler comes to Repare from Bicycle Therapeutics, where she was CMO. Her experience also includes senior roles at Pfizer (NYSE: PFE). In other moves, former Avrobio chief financial officer Katrina Dorton was appointed executive vice president and CFO of Repare. […]